

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/830,139	11/20/2001	Mark Thiede	640100-420	9767	
27162 7	590 09/03/2003				
CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN 6 BECKER FARM ROAD			EXAMINER		
			WOITACH, JOSEPH T		
ROSELAND, NJ 07068			ART UNIT	PAPER NUMBER	
			1632		
			DATE MAILED: 09/03/2003	DATE MAILED: 09/03/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/830,139	THIEDE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Joseph T. Woitach	1632			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM					
THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1)⊠ Responsive to communication(s) filed on <u>20 ∧</u>	lovember 2001 .				
2a) This action is FINAL . 2b) ⊠ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-27</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-27</u> are subject to restriction and/or election requirement. Application Papers					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ary (PTO-413) Paper No(s) Il Patent Application (PTO-152)			

Application/Control Number: 09/830,139

Art Unit: 1632

DETAILED ACTION

Page 2

This application 09/830,139 is a national stage entry of PCT/US99/26927, international filing date November 12, 1999, which claims benefit to US Provisional Application 60/108357,

filed November 13, 1998.

Claims 1-27 are pending.

Election/Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to

which the claims must be restricted.

Group I, claim(s) 1-5, drawn to a method of treating a fetus by administering

mesenchymal stem cells to the fetus.

Group II, claims 6-8, drawn to a method of engrafting mesenchymal stem cells

comprising administering mesenchymal stem cells in utero.

Group III, claim(s) 9-12, drawn to a method of preparing an organ for transplantation

comprising administering mesenchymal stem cells to an organ and harvesting the organ.

Group IV, claims 13-23, drawn to a method of xenotransplantation into a human comprising transplanting an organ made by preparing an organ for transplantation comprising administering mesenchymal stem cells to an organ and harvesting the organ.

Page 3

Group V, claim(s) 24-27, drawn to a hybrid organ of an animal wherein the hybrid organ is of a first species and mesenchymal cells of a second species.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

- A) The invention has no special technical feature that defined the contribution over the prior art, or
- B) Unity of invention between different categories of inventions will only be found to exist if specific combinations of inventions are present. Those combinations include:
 - 1) A product and a special process of manufacture of said product.
 - 2) A product and a process of use of said product.
- 3) A product, a special process of manufacture of said product, and a process of use of said product.
 - 4) A process and an apparatus specially designed to carry out said process.
- 5) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

Application/Control Number: 09/830,139

Art Unit: 1632

The allowed combinations do not include multiple products, multiple methods of using said products, and methods of making multiple products as claimed in the instant application, see MPEP § 1850. In this case, the claims encompass multiple inventions and do not have a special technical feature which link the inventions one to the other, and lack unity of invention. More specifically, mesenchymal stem cells are present in the bone marrow, therefore within the breadth of the method as instantly claimed the invention of group I is anticipated by a bone marrow transplant (for example see Dooren LJ, Padiatr Padol. 1972;7(2):124-7. "Congenital deficiencies of the thymus dependent system of cellular immunity. Treatment by transplantation of bone-marrow or fetal tissues").

Page 4

The inventions above are independent and distinct, each from the other. They have acquired a separate status in the art as a separate subject for inventive effect and require independent searches. The search for each of the above invention is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate the invention of any one Group would not necessarily anticipate or make obvious any of the other groups.

For these reasons restriction for examination is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/830,139

Art Unit: 1632

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

Page 5

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer and inventor of at least one claim remaining in the application.

Any amendment of inventorship must be accompanied by a diligently-filed petition under 37

CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Joseph Woitach whose telephone number is (703)305-3732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Deborah Reynolds, can be reached at (703)305-4051.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group analyst Dianiece Jacobs whose telephone number is (703) 308-2141.

Joseph T. Woitach

Ja Cotacle AU1632